Hepatic Glucose Production
Hepatic Glucose Production - Related Videos
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
0 Views •
2022
This study describes the direct measurement of hepatic glucose production in a polycystic ovary syndrome mouse model by using a stable isotopic glucose tracer via tail vein in both fasting and glucose-rich states in tandem.
06:21
Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model
0 Views •
Cited by 4 •
2023
Here, we present a robust method for in situ perfusion of the mouse liver to study the acute and direct regulation of liver metabolism without disturbing the hepatic architecture but in the absence of extra-hepatic factors.
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
05:52
In Vitro Glucose Depletion Assay: A Fluorescence-Based Method to Quantify Cellular Glucose Uptake via Extracellular Glucose Depletion Measurement
0 Views •
2025
This video demonstrates an in vitro assay to indirectly measure intracellular glucose uptake. The assay uses a fluorescently-labeled glucose analog to establish a correlation between extracellular glucose depletion and intracellular glucose uptake.
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
0 Views •
Cited by 28 •
2017
Here, optimized methods to generate in vivo and in vitro models of hepatic steatosis and to analyze the steatotic phenotypes and related physiological parameters are described.
FAQs
Hepatic glucose production relies on two complementary pathways. Glycogenolysis releases glucose by breaking down glycogen already stored in the liver, whereas gluconeogenesis makes new glucose from lactate, glycerol, and amino acids. Together, these pathways allow glucose release from both an internal reserve and metabolic substrates during fasting and between meals.
When blood glucose falls, glucagon and epinephrine stimulate hepatic glucose production. These hormones promote the liver’s glucose-releasing pathways, helping support blood glucose between meals and during fasting. This hormonal response is central to understanding how the body responds to low glucose and why abnormal hormonal regulation can affect overall glucose balance.
Lactate, glycerol, and amino acids provide distinct starting materials for gluconeogenesis, the pathway that forms new glucose. Their identification clarifies how the liver can continue supplying glucose when stored glycogen is not the relevant source. This distinction helps organize the metabolic context of fasting and disorders involving hepatic glucose regulation.
In clinical medicine, hepatic glucose production provides a framework for interpreting glucose regulation rather than treating blood glucose as an isolated measurement. Its normal contribution between meals and during fasting helps explain the liver’s role in maintaining glucose levels, while abnormal regulation can be considered during assessment of metabolic problems.
Diabetes and insulin resistance are relevant because both require attention to how much glucose the liver releases. Understanding the pathways and their hormonal stimulation connects altered hepatic output with broader metabolic control. This perspective explains why liver glucose regulation is included when evaluating diabetes-related glucose abnormalities and interpreting disrupted blood glucose balance.
Fasting hypoglycemia can be considered in relation to the liver’s ability to maintain blood glucose through glycogenolysis and gluconeogenesis. The relevant context includes both breakdown of stored glycogen and formation of new glucose from lactate, glycerol, or amino acids. This pathway-based view helps organize medical interpretation of low glucose during fasting.
Therapies that alter liver glucose output can influence metabolic control and patient outcomes. Their clinical relevance follows from the liver’s contribution to blood glucose between meals and during fasting. Understanding whether an intervention affects glucose release provides important context for interpreting its effects in diabetes, insulin resistance, or fasting-related glucose abnormalities.